<DOC>
	<DOCNO>NCT01386346</DOCNO>
	<brief_summary>The purpose study see whether give azacitidine cycle chemotherapy prior surgery safe .</brief_summary>
	<brief_title>Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy Resectable Esophageal Cancer</brief_title>
	<detailed_description>Currently patient resectable ( remove surgery ) esophageal cancer receive chemotherapy surgery try shrink tumor remove . This study evaluate whether give azacitidine cycle chemotherapy increase shrinkage tumor prior surgery safe . Azacitidine currently approve Food Drug Administration ( FDA ) treatment myelodysplastic syndrome ( MDS ) . Azacitidine approve FDA use study therefore consider investigational . Because azacitidine give combination epirubicin , oxaliplatin capecitabine , also evaluate safety tolerability azacitidine find dose azacitidine safe give chemotherapy .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma poorly differentiate carcinoma intrathoracic esophagus gastroesophageal junction ( GEJ ) deem resectable thoracic surgeon . No prior chemotherapy esophageal GEJ cancer . ECOG Performance status 02 . Adequate bone marrow , kidney liver function . Ability understand willingness sign write informed consent document . Subjects childbearing potential must agree use effective mean contraception ( men woman ) . Prior malignancy acceptable subject consider cured . In case mean 5year diseasefree period . Patients cervical esophageal cancer esophageal cancer squamous cell carcinoma morphology . Subjects receive investigational agent receive prior chemotherapy esophageal GEJ cancer . History allergic reaction attribute compound similar chemical biologic composition azacitidine , epirubicin , oxaliplatin , capecitabine mannitol . New York Heart Association ( NYHA ) Grade II great congestive heart failure . History myocardial infarction unstable angina within 6 month prior study enrollment . Pregnant ( positive pregnancy test ) lactate woman . Patients active infection , serious intercurrent medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>gastroesophageal junction</keyword>
	<keyword>GEJ</keyword>
	<keyword>esophageal</keyword>
	<keyword>esophagus</keyword>
</DOC>